psoriasis and semaglutide Exploring the Role of GLP-1 Receptor Agonists in Semaglutide therapy decreases epicardial fat
Description
ATTAIN-1 Trial Highlights: - Mean weight loss of ~12.4% over 72 weeks for patients on the highest dose - Participants lost an average of 25 pounds (11.1%) regardless of trial completion - Safety profile consistent with GLP-1 class
GLP-1 use is rebalancing entire shopping baskets
Tesofensine therapy for weight loss at Rewind Anti-Aging of Miami an oral triple reuptake inhibitor with dual-action appetite and metabolism support.
A recent study suggests that a GLP-1 drug, liraglutide, may protect the brains of people with mild Alzheimers disease, slowing cognitive decline by 18% over one year.
Lancet Gastroenterol Hepatol
